WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) will collaborate with Brookline Capital Markets at the upcoming 2nd Targeted Radionuclide Pharmaceuticals (TRPs) Supply Chain & Manufacturing Summit in Boston, MA, from September 24-26, 2024. The event will feature a pivotal workshop titled “Evaluating the Commercial & Pharmaceutical Viability of Radioisotopes to Benchmark Potential.”
The summit will gather TRP industry leaders to tackle key challenges and strategies for commercializing isotopes like actinium-225 and lutetium-177. Discussions will focus on market demand, development hurdles, and potential investment opportunities.
Kemp Dolliver of Brookline Capital Markets highlighted the sector’s promising trajectory, stating, “The radiopharmaceutical sector is at the start of a long upcycle. We will explore market opportunities and the capital markets’ view of them.”
Chris Pak, CEO of MTTI, emphasized their innovative EB technology, which significantly enhances target uptake. “MTTI’s EB technology overcomes many challenges in TRPs today. Our long-acting patented platform provides 8 to 30-fold more uptake at the target compared to the standard TRPs,” Pak noted.
The summit also aims to advance radiopharmaceutical production processes, addressing issues such as isotope production and supply chain management. This gathering is a vital platform for sharing insights to optimize manufacturing and accelerate clinical trials amid industry challenges.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.